Wine is one of the utmost popular drinks consumed worldwide. The escalating demand for wine, because of its unusual taste and health assistances is one of the key aspects boosting the growth of the global wine market. The global wine mar…
BMI View: The Slovakian pharmaceutical market will remain one of the most attractive markets in CEE.
While the authorities continue to impose stringent pricing controls, limiting patented medicine access, there
is clear motivation to widen innovative drug access to the population. Moreover, the pharmaceuticals
regulatory environment is on par with Western European countries.
Headline Expenditure Projections
- Pharmaceuticals: EUR1.91bn (USD2.10bn) in 2015 to EUR1.97bn (USD2.12bn) in 2016; +2.8% in
local currency terms and +0.6% in US dollar terms. Forecast unchanged from last quarter.
- Healthcare: EUR6.15bn (USD6.76bn) in 2015 to EUR6.39bn (USD6.87bn) in 2016; +3.9% in local
currency terms and +1.7% in US dollar terms. Forecast revised slightly upwards from last quarter.
Slovakia's risk index indicates that the country has one of the best business environments in the Central and
Eastern European region, although its placement in the index is moderated by its less-than-impressive
rewards score. Slovakia scores of 57.9 out of 100 and shares fifth positions with Hungary in our Risk/
Reward Index of the Central and Eastern Europe region.